jump to navigation

MBBP Clients Red Crow and MiRTLE Medical Featured in Forbes Article Regarding New Equity Crowdfunding Platform 10/31/2016

Posted by Morse Barnes-Brown Pendleton in Client News, Corporate, Financial Services, Life Sciences, Venture Capital & Private Equity.
Tags: , , , , , , , , , , , , ,
add a comment

MBBP clients Red Crow and MiRTLE Medical are featured in a Forbes article regarding Red Crow’s new equity crowdfunding portal that will be launching in November.  The crowdfunding platform will feature “exclusive and professionally-vetted investment opportunities” for accredited and non-accredited investors.

MiRTLE Medical will have one of the first featured investment opportunities. MiRTLE’s product is a custom designed diagnostic-grade 12-lead electrocardiogram for use during MRI.  MBBP is assisting MiRTLE Medical with its involvement in the crowdfunding platform.

To learn more, read the full Forbes article.

Panel 3 of Life Sciences Series To Be Held On September 22nd! 08/31/2016

Posted by Morse Barnes-Brown Pendleton in Attorney News, Corporate, Events, Financial Services, MBBP news.
Tags: , , , , , , , ,
add a comment

JMH Headshot Photo 2015 (M0846571xB1386)On Thursday, September 22nd, MBBP will host the third panel of our Life Sciences Series, “Funding Models in Biotech“.  The panel will be held at the Cambridge Innovation Center (CIC) from 4:30pm – 6:00pm.

The panel will discuss today’s financing environment for emerging biotech companies, and the many complexities facing these companies in their attempts to find investors.
Corporate Partner John Hession will moderate the panel, which includes the following experts:

Josh Hamermesh, Vice President, Locust Walk

Steve Gullans, Managing Director, Excel Venture Management

Dana Callow, Managing General Partner, Boston Millennia Partners

View the full event details and registration information.  Register soon – seating is limited!

Harvard Stem Cell Institute Teaming Up to Develop Diabetes Cure 08/18/2016

Posted by Morse Barnes-Brown Pendleton in Client News, Intellectual Property, Medical Devices.
Tags: , , , , , , , , , ,
add a comment

A group of Boston-area health institutions, known as the Boston Autologous Islet Replacement Program, are teaming up to develop, test and deploy stem cells to cure diabetes. The group includes the Harvard Stem Cell Institute, Brigham and Women’s Hospital, the Joslin Diabetes Center, Dana-Farber Cancer Institute and Semma Therapeutics.

The innovation began when Doug Melton, Co-Director of Harvard Stem Cell Institute and Co-Founder of Semma Therapeutics, developed a way to turn embryonic stem cells into insulin-producing beta cells without needing to put the cells into mice to mature.  After this discovery, he knew he had to get these beta cells into humans but that it was going to take a group with the proper qualifications.

Melton explains, “No one institution anywhere has the expertise and technical abilities to make this kind of clinical trial possible, but in the unique Harvard biomedical ecosystem, we are able to bring all the necessary expertise and infrastructure to bear.” This new organization has the goal of testing the created beta cells in human patients within three years.

Congratulations to our client Harvard on these exciting new developments! For more information, read the full article.

Blue Stream Laboratories Acquired by Charles River Laboratories 06/28/2016

Posted by Morse Barnes-Brown Pendleton in Client News, Deal News, Life Sciences, MBBP news.
Tags: , , , , , , , , ,
add a comment

blue streamMBBP client Blue Stream Laboratories, an analytical contract research organization supporting the development of complex biologics and biosimilars, was acquired by Charles River Laboratories. Charles River Laboratories is a provider of essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

According to Blue Stream, “The synergy of combining Blue Stream’s core expertise with Charles River’s existing broad portfolio of biopharmaceutical clinical development and supporting services creates a well-established services entity which can fully support biologic and biosimilar development.”

Morse, Barnes-Brown & Pendleton served as counsel to Blue Stream Laboratories and advised them in connection with the structuring, negotiation and documentation of this transaction. Shannon Zollo was the lead corporate attorney on MBBP’s team.

For more information, read the full news release.

PULSE@Mass Challenge Now Open in Boston! 06/10/2016

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences, Medical Devices.
Tags: , , , , , , ,
add a comment

logo_mcPULSE@MassChallenge officially opened in Boston last week, adding to the already increasing number of digital health companies in the area.  MBBP’s Peter Barnes-Brown attended the ribbon cutting ceremony.

Read more about Peter’s thoughts on the growing digital health industry and about the company on our VCs & Startups Blog.

Boston Growing Hub for the Life Sciences Industry 06/08/2016

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences, Venture Capital & Private Equity.
Tags: , , , , , , , ,
add a comment

The Boston Business Journal just announced that at the annual Biotechnology Innovation Organization meeting, Boston was recognized as the city with the largest number of employers in the field of research testing and medical laboratories.  The BBJ explains that from biotech giants such as Biogen to Genzyme to research labs at the prestigious Harvard and MIT, the city is booming in life science employment and early stage development.

Furthermore, MassBio CEO and President Bob Coughlin explains how, “The research shows Massachusetts shines at the earliest stages of industry, with high levels of academic research, NIH and venture capital investments, as well as number of patents earned by our institutions…” Specifically, MA had $9.5 billion in VC investment in a three year term and ranked just behind California in the number of life science patents awarded.

MBBP is proud to represent life sciences companies throughout the greater Boston area (and beyond), in fields including biotechnology, pharmaceuticals and medical devices, along with institutions and investors in a wide range of sophisticated legal matters that arise in connection with the development, protection and commercialization of their diagnostic and therapeutic solutions.

Read the full Boston Business Journal article here.

MBBP Managing Partner Lisa Warren Panelist at MassBio Annual Meeting 03/20/2015

Posted by Morse Barnes-Brown Pendleton in Life Sciences, MBBP news.
Tags: , , ,
add a comment

M0164549On Thursday, March 26th MBBP Managing Partner Lisa Warren will sit as part of a panel at The MassBio Annual Meeting.  The discussion will be on the topic of Externalizing Pharma R&D.

The MassBio Annual Meeting is a two day event that focuses on the most timely and critical challenges facing the Massachusetts biotechnology industry. As MassBio’s largest event, drawing close to 400 industry leaders, the meeting program is compiled by a Steering Committee and includes keynote presentations, plenary discussions, two panel tracks (Better Business and Trends in Science), and extensive networking opportunities.

For more information contact MassBio.

M&A Today: First Issue of 2015 01/06/2015

Posted by Morse Barnes-Brown Pendleton in M&A.
Tags: , , , , ,
add a comment

MA Today BannerWe’re starting 2015 with plenty of M&A news! Articles include:

To learn more on all these topics the full newsletter  can be found on our M&A Blog.

IntegraGen Opens Subsidiary in Cambridge 11/08/2010

Posted by Morse Barnes-Brown Pendleton in Client News.
Tags: , ,
add a comment

IntegragenMBBP client IntegraGen, Inc., a French biotech company, announced it will be opening a U.S. subsidiary in Cambridge, Massachusetts which will help to conduct its clinical research initiatives on early identification of children at risk of autism. IntegraGen’s corporate headquarters is located in Evry, France where it focuses on gene discovery and providing state of the art genotyping services to the research community through the Company’s Genetic Services Business. IntegraGen CEO, Dr. Bernard Courtieu, discusses the benefits of the expansion:

We have decided to locate IntegraGen’s U.S. subsidiary in Cambridge as a result of Massachusetts’ commitment to attracting and supporting the life sciences, the proximity to world-renowned academic institutions, and the highly qualified talent pool in the area. We believe this will be an ideal location to support our strategic business efforts in the United States and further strengthen the strong ties between biotechnology companies based in France and the Commonwealth of Massachusetts.

Click here to see the full press release.

%d bloggers like this: